News
GlobalData on MSN22h
EC approves BeOne’s Tevimbra for nasopharyngeal carcinomaBeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...
Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...
News Medical on MSN4d
Landmark discovery reshapes understanding of key cancer protein MCL-1Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...
The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...
While cancer has seen some significant advancements in treatments that have shown promise and increased lifespan, however, it ...
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...
As a result, drugs that inhibit MCL-1 can inadvertently damage healthy tissues that rely on this protein for energy, especially in organs with high energy demand like the heart and liver, leading to ...
The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but ...
The Cool Down on MSN6d
Scientists make astonishing discovery that could protect food supply from emerging threats: 'We can now design long-sought tools'Scientists from Rutgers University and Brookhaven National Laboratory collaborated on this ongoing research and published a ...
DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback